Comparison
Retatrutide vs MariTide
Retatrutide alongside MariTide (maridebart cafraglutide), compared on developer, mechanism, administration, development stage, trial population, reported efficacy, study duration and regulatory status.
Side by side
Comparison table
| Field | Retatrutide | MariTide (maridebart cafraglutide) |
|---|---|---|
| Developer | Eli Lilly and Company | Amgen |
| Mechanism | GLP-1 / GIP / Glucagon triple agonist | GIP receptor antagonist / GLP-1 agonist |
| Administration | Once-weekly subcutaneous | Monthly or less frequent subcutaneous |
| Development Stage | Phase 3 | Phase 3 |
| Studied Population | Obesity ± type 2 diabetes | Obesity, type 2 diabetes |
| Regulatory Status | Investigational | Investigational |
Cross-trial comparisons should be interpreted cautiously because study populations, trial designs, treatment durations and endpoints may differ.
Weekly briefing
The Retatrutide Report
The most important retatrutide clinical trial, research and regulatory developments, once a week.
No spam. Unsubscribe anytime. By subscribing, you agree to receive the Retatrutide Report by email. You can unsubscribe at any time. Privacy Policy.